Search research articles
Contact Us
Filters
Showing results (151-160 of 280) with videos related to
Page
of 28
Sort By:
Internal Medicine Journal
|
March 8, 2022
Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction
Mansi Tiwary, Tamara Y Milder, Sophie L Stocker, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
November 15, 2019
Comparison of calcaneal quantitative ultrasound and bone densitometry parameters as fracture risk predictors in type 2 diabetes mellitus
J W J Lasschuit, J R Center, J R Greenfield, et al.
Diabetes Care
|
April 9, 2013
Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes
Jessica Chang, Tongzhi Wu, Jerry R Greenfield, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 22, 2017
Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity
Katherine T Tonks, Christopher P White, Jacqueline R Center, et al.
Internal Medicine Journal
|
August 7, 2023
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation
Tamara Y Milder, Sophie L Stocker, Melissa T Baysari, et al.
European Journal of Clinical Pharmacology
|
August 5, 2019
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease
Tamara Y Milder, Sophie L Stocker, Dorit Samocha-Bonet, et al.
Biochemistry
|
July 22, 1997
Antenna excited state decay kinetics establish primary electron transfer in reaction centers as heterogeneous
P D Laible, S R Greenfield, M R Wasielewski, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 10, 2024
Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial
Ruth Frampton, Jennifer R Snaith, Samantha Hocking, et al.
Internal Medicine Journal
|
September 20, 2021
Effect of fasting ketosis and type 1 diabetes on alcohol breath analysis technology used in Australia
Daniel P Heidegger, Kirsten E Neal, Shivani K Patel, et al.
Journal of Diabetes Science and Technology
|
December 24, 2024
Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies
Viral N Shah, Rikke M Agesen, Lars Bardtrum, et al.
Page
of 28
Search research articles
Search
Showing results (151-160 of 280) with videos related to
Sort By:
Page
of 28
Internal Medicine Journal
|
March 8, 2022
Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction
Mansi Tiwary, Tamara Y Milder, Sophie L Stocker, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
November 15, 2019
Comparison of calcaneal quantitative ultrasound and bone densitometry parameters as fracture risk predictors in type 2 diabetes mellitus
J W J Lasschuit, J R Center, J R Greenfield, et al.
Diabetes Care
|
April 9, 2013
Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes
Jessica Chang, Tongzhi Wu, Jerry R Greenfield, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 22, 2017
Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity
Katherine T Tonks, Christopher P White, Jacqueline R Center, et al.
Internal Medicine Journal
|
August 7, 2023
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation
Tamara Y Milder, Sophie L Stocker, Melissa T Baysari, et al.
European Journal of Clinical Pharmacology
|
August 5, 2019
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease
Tamara Y Milder, Sophie L Stocker, Dorit Samocha-Bonet, et al.
Biochemistry
|
July 22, 1997
Antenna excited state decay kinetics establish primary electron transfer in reaction centers as heterogeneous
P D Laible, S R Greenfield, M R Wasielewski, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
June 10, 2024
Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial
Ruth Frampton, Jennifer R Snaith, Samantha Hocking, et al.
Internal Medicine Journal
|
September 20, 2021
Effect of fasting ketosis and type 1 diabetes on alcohol breath analysis technology used in Australia
Daniel P Heidegger, Kirsten E Neal, Shivani K Patel, et al.
Journal of Diabetes Science and Technology
|
December 24, 2024
Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies
Viral N Shah, Rikke M Agesen, Lars Bardtrum, et al.
Page
of 28